100873-41-4

Upstream product

• 40064-34-4 4-piperidone monohydrochloride monohydrate 
• 588-63-6 3-phenoxypropyl bromide 
• 41979-39-9 4-piperidone hydrochloride 
• 101867-50-9 3,3'-(3-phenoxy-propylimino)-di-propionic acid dimethyl ester 

Downstream Products

• 1204739-69-4 2-(2,4-difluorophenyl)-3-[1-(3-phenoxypropyl)piperidin-4-ylideneamino]-1-(1H-1,2,4-trazol-1-yl)propan-2-ol 

Relevant academic research and scientific papers

LSD1 Inhibitors

The present invention relates to compounds that inhibit LSD1 activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

Design, synthesis, and antifungal activity of novel conformationally restricted triazole derivatives

A series of new triazole derivatives were designed and synthesized on the basis of the active site of lanosterol 14α-demethylase from Candida albicans (CACYP51). 2-(2,4-Difluorophenyl)-3-(methyl-(3-phenoxyalkyl)amino)-1- (1H-1,2,4-triazol-1-yl)propan-2-ols show excellent in-vitro activity against most of the tested pathogenic fungi. The MIC80 value of compound 8a against Candida albicans is 0.01 μM, which provides a good starting template for further structural optimization. The binding modes of the designed compounds were investigated by flexible molecular docking. The compounds interacted with CACYP51 through hydrophobic, van-der-Waals, and hydrogenbonding interactions.

4-substituted piperidine analogs and their use as subtype selective NMDA receptor antagonists

PCT No. PCT/US96/20872 Sec. 371 Date Sep. 16, 1998 Sec. 102(e) Date Sep. 16, 1998 PCT Filed Dec. 20, 1996 PCT Pub. No. WO97/23216 PCT Pub. Date Jul. 3, 1997Novel 4-substituted piperidine analogs, pharmaceutical compositions containing the same and the method of using 4-substituted piperidine analogs are selective active antagonists of N-methyl-D-aspartate (NMDA) receptor subtypes for treating conditions such as stroke, cerebral ischemia, central nervous system trauma, hypoglycemia, psychosis, anxiety, migraine headaches, glaucoma, CMV retinitis, aminoglycoside antibiotics-induced hearing loss, convulsions, chronic pain, opioid tolerance or withdrawal, urinary incontinence or neurodegenerative disorders, such as lathyrism, Alzheimer's Disease, Parkinsonism and Huntington's Disease are described.